Experience
Elan Corporation PLC
Andrx Pharmaceutical
In this ANDA case, our client, Elan Corporation PLC, filed suit to prevent infringement of its patent directed to naproxen formulations for once-daily oral administration. The district court held Elan’s patent claims invalid in view of Elan’s offer to license technology directed generally to the joint R&D of such pharmaceutical products. The Federal Circuit vacated the district court’s holding and remanded the case so that Elan could pursue its claims on the merits. This case has a far-reaching impact in the pharmaceutical industry, affecting views toward R&D licensing programs and the ability to negotiate licensing programs before a patent application is filed.
Elan Corporation PLC v. Andrx Pharmaceutical, 0:98-cv-07164; 0:00-cv-07057; 0:05-cv-60158, S.D. Fla., Judge Jordan
Elan Corporation PLC v. Andrx Pharmaceutical, 03-1354, -1355, -1386, -1387, Fed. Cir., Judges Michel, Lourie, Dyk
Finnegan client Elan protected against antitrust claims based on ANDA settlement
Elan Corporation PLC
Elan Pharmaceuticals, Inc. v. Eon Labs, Inc.
Elan Pharmaceuticals, Inc.
Elan Pharmaceuticals, Inc. v. Ivax Pharmaceuticals, Inc.
Elan Pharmaceuticals, Inc.
Elan Corp., PLC v. Brightstone Pharma
Elan Corp., PLC
BCL-2 inhibitors licensing agreement for Fochon Pharmaceuticals, Ltd.
Fochon Pharmaceuticals, Ltd.
Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc.
Elan Pharmaceuticals, Inc.
InnoPharma Licensing, Inc.; Lupin Ltd.; and Metrics, Inc. v. Senju Pharmaceuticals Co.
Bausch Health Companies
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.